Kisspeptin is distributed not only in brain areas for regulating reproduction but also in nuclei involved in feeding control. Whether kisspeptin alters food intake is unknown in mice. We examined how kisspeptin-10 influences feeding after intracerebroventricular injection in mice using automated monitoring. Kisspeptin-10 (0.3, 1, and 3 lg/mouse) dose-dependently inhibited the feeding response to an overnight fast by 50, 95, and 90% respectively, during the 2-3 h period postinjection. The 1lg/mouse dose reduced the 4-h cumulative food intake by 28% whereas intraperitoneal injection (10 lg/mouse) did not. The decreased 4-h food intake was due to reduced meal frequency ( -45%/4 h), whereas meal size and gastric emptying were not altered. These data suggest that kisspeptin may be a negative central regulator of feeding by increasing satiety.
Introduction
The 54-amino acid kisspeptin was discovered in 1996 as the gene product of the metastasis-suppressor gene [1] . The name derived from its initial function as a suppressor sequence and the letters KI were added to form KISS, in keeping with the place of its discovery, Hershey (production site of the 'Hershey's chocolate kisses'). Kisspeptin binds to the G-protein-coupled receptor, GPR54 [2] , now referred to as kisspeptin receptor (Kiss1r) [3] . As the discovery that mutations of the human KISS1R gene were associated with idiopathic hypothalamic hypogonadism and impaired pubertal maturation [4, 5] , a finding confirmed in transgenic mice [6] , kisspeptin has been identified as a major regulator governing the mammalian hypothalamic-pituitarygonadal axis and puberty onset (see [6] for review).
Besides the full length C-terminally amidated 55 aminoacid peptide, kisspeptin-54 (also referred to KP-54 [3] ), the C-terminal cleavage fragments such as kisspeptin-10, kisspeptin-13, and kisspeptin-14 also activate the receptor with the same affinity and possess biological activity [3, 7] . Kisspeptin is widely distributed in the rat and mouse brain including the amygdala, hypothalamic arcuate nucleus (Arc), paraventricular nucleus, dorsomedial hypothalamus, and locus coeruleus [8, 9] . Similarly, Kiss1r gene was reported to be widely expressed in the mouse brain encompassing sites such as the hippocampus, posterior hypothalamus, medial preoptic area, medial septum, and cerebellum [10, 11] . However, in the mouse Arc, divergent reports showed either no expression in transgenic GPR54 LacZ knockin mice [10] or expression in all Arc rostrocaudal regions assessed by quantitative real-time PCR [11] . Kisspeptin's distribution, especially its expression in key food intake regulatory nuclei such as Arc and paraventricular nucleus [12] , suggests a role for kisspeptin in the regulation of energy homeostasis [13] and food intake, which has been little explored and so far only in rats [14, 15] .
Therefore, in this study, we investigated the central action of kisspeptin-10 to influence food intake in mice fed ad libitum or fasted overnight using acute injection of the peptide into the brain ventricle (intracerebroventricularly, i.c.v.) compared with a 10-times higher dose injected intraperitoneally (i.p.). As knowledge of the food intake microstructure is essential to characterize the feeding modulatory properties of a compound, we examined the influence of i.c.v. kisspeptin-10 on the feeding micropattern assessed by an automated episodic food intake monitoring device adapted for mice that was established in our earlier studies [16] . In view that slowing of gastric emptying and prolonged gastric distention impact on subsequent food intake [17] , we also examined whether kisspeptin injected i.c.v. alters gastric emptying of a solid meal in overnight fasted mice.
Materials and methods

Animals
Adult male C57Bl/6 mice (6-8 weeks, Harlan Laboratories, San Diego, California, USA) were group-housed four per cage under controlled illumination (6 : 00-18 : 00 h) and temperature (21-231C). Animals had ad libitum access to purified standard rodent diet (AIN-93M, Research Diets, Inc., Jules Lane, New Brunswick, New Jersey, USA) and tap water. Protocols were approved by the Veterans Administration Institutional Animal Care and Use Committee (# 99127-07).
Injections
Acute injection into the lateral brain ventricle (5 ml) was administered under short isoflurane anesthesia (2-3 min, 4.5% vapor concentration in oxygen; VSS, Rockmart, Georgia, USA) as in our earlier studies [16, 18] . The injection site was localized at the apex of the equal triangle between the eyes and the back of the head, cleaned with Povidone iodine 10% (Aplicare Inc., Meriden, Connecticut) and the skull punctured manually at the point of least resistance with a 30-gauge needle equipped with a polyethylene tube (leaving 4 mm of the needle tip exposed) and attached to a Hamilton syringe. Mice completely recovered from anesthesia within 5 min. The accuracy of the injections was confirmed in our earlier studies by injecting cresyl violet dye i.c.v. under similar conditions in 50 mice [18] . I.p. injections (100 ml) were performed in conscious handrestrained mice handled for this position on 3 days during the week before the experiment.
Food intake measurement
The microstructure analysis of food intake was assessed by the BioDAQ episodic Food Intake Monitor for mice (BioDAQ, Research Diets, Inc., New Brunswick, New Jersey, USA) as described in detail in our earlier study [16] . This system allows the continuous monitoring of meal patterns in undisturbed mice with minimal human interference. Mice habituated to these cages and feeding from the hopper within 3-4 days, indicated by normal food intake and regular body weight gain.
The system weighs the food hopper (± 0.01 g) second by second and detects not eating as weight stable, and eating as weight unstable. Meals consist of one or more bouts (changes in stable weight before and after a bout) separated by an inter-meal interval (IMI, Z 5 min). The minimum meal amount was defined as 0.02 g. Therefore, food intake was considered as one meal when the feeding bouts occurred within 5 min of the previous response and their sum was greater than or equal to 0.02 g; if feeding bouts were more than or equal to 5 min apart, they were considered as a new meal. Meal parameters include meal/ bout frequency, meal size, and duration, total time spent eating (time in minutes or percentages), latency to first meal, IMI, rate of ingestion, and satiety ratio (average IMI divided by the average meal size).
Experiments were started after 1 week of habituation. Overnight fasted mice were i.c.v. injected with kisspeptin-10 (0.3, 1, or 3 mg/mouse in saline containing 0.1% bovine serum albumin, Phoenix Pharmaceuticals Inc., Burlingame, California, USA) or vehicle (saline containing 0.1% bovine serum albumin) at 9 : 00 h and microstructure of food ingestion was recorded for 24 h. The maximal effective i.c.v. dose of 1 mg/mouse was used for all other studies. Ad libitum fed mice received kisspeptin-10 or vehicle at the onset of the dark phase (17:50 h) and food intake microstructure was assessed for 24 h. In another study, ad libitum fed mice were i.c.v. injected with kisspeptin-10 or vehicle during the light phase at 9 : 00 h and food intake microstructure monitored for 24 h. In one study, overnight fasted mice were injected i.p. with kisspeptin-10 (10 mg/mouse) or vehicle at 9 : 00 h and food intake microstructure was assessed for 24 h. Experiments were repeated in a crossover design in the same batch of mice for each treatment.
Gastric emptying
Gastric emptying of rodent diet was determined as in our earlier studies [18] . Briefly, mice were fasted overnight and refed with preweighed standard chow starting at 8 : 00 h for 1 h. Then, food and water were removed, mice injected i.c.v. with kisspeptin-10 (1 mg/mouse) or vehicle and gastric emptying assessed 3 h later. Mice were killed by cervical dislocation, the stomach quickly removed, the stomach content weighed, and gastric emptying calculated as (1-gastric content/food intake) Â 100.
Statistical analysis
Data were expressed as mean ± standard error of the mean and were analyzed by one-way analysis of variance (ANOVA) followed by Tukey post hoc test or two-way ANOVA followed by Holm-Sidak method. Differences between groups were considered significant when P value was less than 0.05.
Results
Kisspeptin-10 (0.3, 1, and 3 mg/mouse) injected i.c.v. in overnight fasted mice induced a dose-related decrease in light phase food intake ( -50, -95, and -90%, respectively) during the 2-3 h period postinjection reaching statistical significance at 1 and 3 mg/mouse (P < 0.05; Fig. 1a ), whereas there was no inhibition at the 0-1, 1-2, and 3-4 h periods postinjection. Two-way ANOVA showed a significant influence of treatment [F(3,104) = 4.1, P < 0.01], time [F(3,104) = 222.4, P < 0.001], and treatment Â time [F(9,104) = 2.1, P < 0.05]. On the basis of these results, the dose of 1 mg/mouse was selected for further analyses. The reduction during the 2-3 h period resulted in a significant decrease in the 4-h cumulative food intake ( -28%, P < 0.05; Fig. 1b ) which was still observed at 12 h compared with vehicle ( -19%, P < 0.05; Fig. 1c ). During the 12-16 h period, there was a compensatory increase in food intake ( Fig. 1b) resulting in similar 24-h food intake values in i.c.v. kisspeptin-10 and vehicle-injected groups (Fig. 1c ).
As the main effect was observed during the first 4 h postinjection, the food intake microstructure was assessed in this period. Kisspeptin-10 injected i.c.v. significantly decreased meal frequency ( -45%, P < 0.05; Fig. 2a ), total meal time ( -31%, P < 0.05; Fig. 2e ) and time spent in meals ( -31%, P < 0.05; Fig. 2f ), increased IMIs ( + 137%, P < 0.05; Fig. 2g ), and satiety ratio ( + 69%, P < 0.05; Fig. 2i ) compared with vehicle, whereas bout frequency (Fig. 2b) , meal size (Fig. 2c ), duration of meals (Fig. 2d ), and eating rate (Fig. 2h) were not significantly changed (P > 0.05).
The decreased food intake was not associated with alterations of gastric emptying. Indeed, under the same conditions, kisspeptin-10 (1 mg/mouse, i.c.v.) did not modify gastric transit of a solid meal in overnight fasted mice assessed at 3 h after injection during the light phase compared with vehicle (34.9 ± 8.1 vs. 37.0 ± 5.6%, n = 6/group, P > 0.05). In contrast, i.p. injection of kisspeptin-10 at a 10-times higher dose than i.c.v. (10 mg/mouse) did not influence the light phase food intake in overnight fasted mice (Table 1) .
When tested in ad libitum fed mice either during the light or at the onset of the dark phase, kisspeptin-10 (1 mg/mouse, i.c.v.) had no effect on food intake or microstructure parameters compared with vehicle (Table 1 ).
Discussion
In this study, we show for the first time that kisspeptin-10 injected into the lateral brain ventricle at a low dose (1 mg = 0.8 nmol) during the light phase induced a peak 95% inhibition of the hourly food intake response to an overnight fast in mice. The inhibitory action was doserelated, occurred mainly during the 2-3 h period postinjection reflecting a delayed onset, was long-lasting as shown by the 12-h reduction of cumulative food intake postinjection and not associated with delayed gastric emptying of ingested food. The lack of effect of a 10-times higher dose injected i.p. supports that the anorexigenic effect of kisspeptin-10 represents a centrally mediated action and not a leakage of the peptide into the periphery. Therefore, the delayed onset of feeding inhibition may point toward time needed to modulate mRNA/protein expression of anorexigenic brain signaling. These data, coupled with the well-documented suppression of hypothalamic Kiss-1 mRNA expression by fasting or other states of negative energy balance in rats [13, 14] , may collectively suggest an anorexigenic role for kisspeptin in the central regulation of food intake.
In contrast, the same low i.c.v. dose was ineffective to alter food intake when injected at the onset of the dark phase in nonfasted mice. These data indicate that the food intake suppressive effect of kisspeptin-10 is specific to brain circuitries involved in the feeding response to a fast and not the nocturnal drive to eat under ad libitum feeding conditions. Fasting is well established to increase the orexigenic hypothalamic neuropeptide Y (NPY), whereas mRNA expression of the food intake suppressing proopiomelanocortin (POMC) is decreased [19] . A recent in-vitro electrophysiological study in mice showed that kisspeptin activates POMC hypothalamic green fluorescent protein expressing neurons, whereas NPY neurons are inhibited [11] . Immunohistochemical and real-time PCR expression studies showed that kisspeptin positive fibers are located in close proximity to POMC neurons as well as that Kiss1r is expressed in these neurons [11] . In addition, the posterior hypothalamus is a prominent expression site of the Kiss1r [10] . Moreover, the orexigenic melanin-concentrating hormone activates neurons that are inhibited by kisspeptin [20] . Taken together, these data suggest that the inhibitory effect of kisspeptin-10 on the refeeding response to a fast may be exerted through an inhibition of central NPY and melanin-concentrating hormone signaling as well as the recruitment of POMCderived a-melanocyte-stimulating hormone. In addition, almost half of the kisspeptin positive neurons in the murine Arc express the leptin receptor [21] suggesting the interaction with another key hormone regulating food intake and energy homeostasis that reduces food intake by decreasing the number of meals but not size of the [22] . However, the POMC-derived a-melanocytestimulating hormone decreases food intake by selectively reducing meal size but not frequency [23] , whereas NPY increases the number of meals [24] . In this study we showed that kisspeptin-10 decreases food intake by increasing IMIs leading to the reduction of meal number, whereas the meal size was not altered. This pattern is indicative of inducing satiety (mechanisms causing later onset of the next meal after one completed meal [25] ), whereas satiation (mechanisms causing meal termination [25] ) is not altered. Therefore, on the basis of earlier and present findings, it may be speculated that a negative central interaction between kisspeptin and orexigenic NPY pathways along with a positive interaction with anorexigenic leptin signaling exists. However, it cannot be ruled out that kisspeptin also acts by modulating the processing of other gut-derived satiety signals reaching the brain or potentiate their interactions [12] and thereby induces satiety.
In contrast to the present findings in mice, i.c.v. injection of kisspeptin-10 at similar doses (1.3 or 3.8 mg/rat) in rats under fasted or ad libitum feeding conditions did not alter food intake during the light or dark phase whereas positive peptide controls had the expected effects [14, 15] . Whether species differences or the automated noninterfering food intake monitoring versus manual assessment account for these divergent results warrants further investigation.
Conclusion
This study in mice shows that kisspeptin-10 acts centrally to reduce the light phase food intake response to an overnight fast with a delayed onset by reducing meal frequency associated with prolonged inter-meal intervals indicating a stimulatory effect on satiety. These data, along with the expression of kisspeptin in major feeding regulatory brain nuclei and its down-regulation by fasting, unravel a potential negative regulatory role of central kisspeptin in the control of feeding in mice.
